Alireza Morovat

Dr. Alireza Morovat

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
PLPei Jin Lim
Pei Jin Lim
TDTiago L Duarte
Tiago L Duarte
JAJoão Arezes
João Arezes
DGDaniel Garcia-Santos
Daniel Garcia-Santos
AHAmel Hamdi
Amel Hamdi
ADAlexander Drakesmith
Alexander Drakesmith

22 February 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JMJohn Muthii Muriuki
John Muthii Muriuki
AMAlexander J. Mentzer
Alexander J. Mentzer
RMRuth Mitchell
Ruth Mitchell
EWEmily L. Webb
Emily L. Webb
AEAnthony O. Etyang
Anthony O. Etyang
SASarah Atkinson
Sarah Atkinson
Malaria and iron deficiency (ID) are common and interrelated public health problems in African children. Observational data suggest that interrupting malaria transmission reduces the prevalence of ID1. To test the hypothesis that malaria might cause ID, we used sickle cell trait (HbAS, rs334), a genetic variant that confers specific protection against malaria2, as an instrumental variable in Mendelian randomization analyses. HbAS was associated with a 30% reduction in ID among children living in malaria-endemic countries in Africa (n = 7,453), but not among individuals living in malaria-free areas (n = 3,818). Genetically predicted malaria risk was associated with an odds ratio of 2.65 for ID per unit increase in the log incidence rate of malaria. This suggests that an intervention that halves the risk of malaria episodes would reduce the prevalence of ID in African children by 49%.

21 August 2017 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMAlireza Morovat
Alireza Morovat
GWGayani Weerasinghe
Gayani Weerasinghe
VNVictoria Nesbitt
Victoria Nesbitt
MHMonika Hofer
Monika Hofer
TAThomas Agnew
Thomas Agnew
JPJoanna Poulton
Joanna Poulton
Recent work has suggested that fibroblast growth factor-21 (FGF-21) is a useful biomarker of mitochondrial disease (MD). We routinely measured FGF-21 levels on patients who were investigated at our centre for MD and evaluated its diagnostic performance based on detailed genetic and other laboratory findings. Patients’ FGF-21 results were assessed by the use of age-adjusted z-scores based on normalised FGF-21 values from a healthy population. One hundred and fifty five patients were investigated. One hundred and four of these patients had molecular evidence for MD, 27 were deemed to have disorders other than MD (non-MD), and 24 had possible MD. Patients with defects in mitochondrial DNA (mtDNA) maintenance (n = 32) and mtDNA rearrangements (n = 17) had the highest median FGF-21 among the MD group. Other MD patients harbouring mtDNA point mutations (n = 40) or mutations in other autosomal genes (n = 7) and those with partially characterised MD had lower FGF-21 levels. The area under the receiver operating characteristic curve for distinguishing MD from non-MD patients was 0.69. No correlation between FGF-21 and creatinine, creatine kinase, or cardio-skeletal myopathy score was found. FGF-21 was significantly associated with plasma lactate and ocular myopathy. Although FGF-21 was found to have a low sensitivity for detecting MD, at a z-score of 2.8, its specificity was above 90%. We suggest that a high serum concentration of FGF-21 would be clinically useful in MD, especially in adult patients with chronic progressive external ophthalmoplegia, and may enable bypassing muscle biopsy and directly opting for genetic analysis. Availability of its assay has thus modified our diagnostic pathway.

11 June 2013 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
AMAlireza Morovat
Alireza Morovat
ACAnthony Catchpole
Anthony Catchpole
AMAngélique Meurisse
Angélique Meurisse
ACAgnès Carlisi
Agnès Carlisi
ABAnne-Catherine Bekaert
Anne-Catherine Bekaert
ÉCÉtienne Cavalier
Étienne Cavalier
Background: We carried out a technical evaluation of the Immunodiagnostic Systems (IDS) automated intact procollagen-I N-terminus propeptide (PINP) assay on the iSYS platform, and established reference intervals for PINP in both adults and children. Methods: Assay imprecision, recovery and interference were studied. Serum and plasma values were compared, and PINP stability was assessed. Using 828 specimens, IDS iSYS intact PINP and Roche E170 total PINP values were compared. Specimens from 597 adults and 485 children and adolescents were used to establish reference intervals for intact PINP. Results: The method demonstrated good recovery and acceptable imprecision. The assay was unaffected by icterus and lipaemia, but haemolysis decreased measured PINP. Serum and plasma values were comparable. There was a non-linear relation between IDS intact and Roche total PINP values. Pre- and post-menopausal women had comparable PINP values, but there was a difference between women of different age groups. Serum PINP in men showed a decline in young age up to 45 years, but remained steady thereafter. Separate reference intervals were established for four age groups in women and for two age groups in men. Data for children were partitioned into four-year age groups, and these showed PINP to be high with no major gender differences until 12 years of age. Thereafter, values in females decreased in 13–16 years age groups and further in 17–20 years age groups, whereas PINP increased in boys of 13–16 years of age with a subsequent decline at 17–20 years. Conclusions: The IDS iSYS PINP intact assay appears to be reliable. We have established gender- and age-related reference intervals for children and adults based on a relatively large healthy North European population.

25 March 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
RMReagan Moseti Mogire
Reagan Moseti Mogire
JMJohn Muthii Muriuki
John Muthii Muriuki
AMAlireza Morovat
Alireza Morovat
AMAlexander J. Mentzer
Alexander J. Mentzer
EWEmily L. Webb
Emily L. Webb
SASarah Atkinson
Sarah Atkinson
Vitamin D regulates the master iron hormone hepcidin, and iron in turn alters vitamin D metabolism. Although vitamin D and iron deficiency are highly prevalent globally, little is known about their interactions in Africa. To evaluate associations between vitamin D and iron status we measured markers of iron status, inflammation, malaria parasitemia, and 25-hydroxyvitamin D (25(OH)D) concentrations in 4509 children aged 0.3 months to 8 years living in Kenya, Uganda, Burkina Faso, The Gambia, and South Africa. Prevalence of iron deficiency was 35.1%, and prevalence of vitamin D deficiency was 0.6% and 7.8% as defined by 25(OH)D concentrations of <30 nmol/L and <50 nmol/L, respectively. Children with 25(OH)D concentrations of 75 nmol/L. 25(OH)D concentrations variably influenced individual markers of iron status. Inflammation interacted with 25(OH)D concentrations to predict ferritin levels. The link between vitamin D and iron status should be considered in strategies to manage these nutrient deficiencies in African children.

6 September 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
JMJohn Muthii Muriuki
John Muthii Muriuki
AMAlexander J. Mentzer
Alexander J. Mentzer
GBGavin Band
Gavin Band
JGJames J. Gilchrist
James J. Gilchrist
TCTommy Carstensen
Tommy Carstensen
SASarah Atkinson
Sarah Atkinson
Iron acquisition is critical for life. Ferroportin (FPN) exports iron from mature erythrocytes, and deletion of the Fpn gene results in hemolytic anemia and increased fatality in malaria-infected mice. The FPN Q248H mutation (glutamine to histidine at position 248) renders FPN partially resistant to hepcidin-induced degradation and was associated with protection from malaria in human studies of limited size. Using data from cohorts including over 18,000 African children, we show that the Q248H mutation is associated with modest protection against anemia, hemolysis, and iron deficiency, but we found little evidence of protection against severe malaria or bacteremia. We additionally observed no excess Plasmodium growth in Q248H erythrocytes ex vivo, nor evidence of selection driven by malaria exposure, suggesting that the Q248H mutation does not protect from malaria and is unlikely to deprive malaria parasites of iron essential for their growth.